News

Revolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid Tumors
Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best high short interest stocks with huge upside potential. On June 30, ...
Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain
Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...
Why Summit Therapeutics Stock Soared 8% Higher Today
A large, well-capitalized peer is apparently interested in a partnership deal with the company. The media outlet in question ...
AOL6mon
Where Will Summit Therapeutics Be in 5 Years? - AOL
Summit Therapeutics (NASDAQ: SMMT) has risen in prominence in the past two years thanks to a promising pipeline candidate, ivonescimab, a potential cancer treatment. It doesn't have a single drug ...
2 Soaring Stocks With More Upside Potential to Buy and Hold
Second, SoFi could grow its revenue even without expanding its membership base, by cross-selling additional products to its ...
Summit Therapeutics (SMMT) Rated Buy on Ivonescimab’s Cancer-Fighting Potential
Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the 30 stocks expected to beat the market by 20 percentage points this ...
Zacks Investment Research on MSN3d
Wall Street Analysts Believe Summit Therapeutics (SMMT) Could Rally 63.02%: Here's is How to Trade
Shares of Summit Therapeutics PLC (SMMT) have gained 2.8% over the past four weeks to close the last trading session at $21.2 ...